These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 6339040)

  • 21. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin.
    Bilen CY; Inci K; Erkan I; Ozen H
    J Urol; 2003 May; 169(5):1702-5. PubMed ID: 12686812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer.
    Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y
    Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
    Winters WD; Lamm DL
    Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways.
    Hudson MA; Brown EJ; Ritchey JK; Ratliff TL
    Cancer Res; 1991 Jul; 51(14):3726-32. PubMed ID: 2065329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Two cases of successful treatments with steroid for local and systemic hypersensitivity reaction following intravesical instillation of Bacillus Calmette-Guerin].
    Shimasaki N; Yamasaki I; Kamada M; Syuin T
    Hinyokika Kiyo; 2001 Apr; 47(4):281-4. PubMed ID: 11411106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes in the activity of natural killer cells in superficial bladder cancer during intravesical BCG therapy].
    Samodai L; Dankó K
    Orv Hetil; 1992 Sep; 133(36):2283-6, 2291-2. PubMed ID: 1408062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer.
    Bennett JA; Gruft H; McKneally MF; Zelterman D; Crispen RG
    Cancer Res; 1983 Sep; 43(9):4183-90. PubMed ID: 6347367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
    Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM
    Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The fate of bacillus Calmette-Guerin after intravesical instillation.
    Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
    J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells.
    Lattime EC; Gomella LG; McCue PA
    Cancer Res; 1992 Aug; 52(15):4286-90. PubMed ID: 1638541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer.
    Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
    J Urol; 1984 Jan; 131(1):139-42. PubMed ID: 6418894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells.
    Lodillinsky C; Umerez MS; Jasnis MA; Casabé A; Sandes E; Eiján AM
    Int J Mol Med; 2006 Feb; 17(2):269-73. PubMed ID: 16391825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D; Höltl W; Bassi P; Brausi M; Ferrari P; de Balincourt C; Sylvester R;
    J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.